Jazz Pharmaceuticals price target raised to $87 from $76 at Lazard Capital Lazard Capital raised its price target fort Jazz Pharmaceuticals citing expectations for robust Xyrem revenue growth and keeps a Buy rating on the stock.
BMO's pharma predictions for rest of year include take on Mylan, Perrigo BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.